Bli medlem
Bli medlem

Du är här

2022-05-11

EQL Pharma out-license Mellozzan to a leading French Company in ADHD

EQL Pharma has today entered into an exclusive out-licensing agreement with French company H.A.C. Pharma for EQL's proprietary product Mellozzan (melatonin) for France. The agreement is in practice without a set time limit and applies to tablets in six different strengths as well as an oral solution, where the latter is newly developed and ready to be sent to authorities for registration.
 

Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. It can also be given as a short-term treatment to adults with sleep disorders caused by jet lag. Mellozzan was launched by EQL in Sweden in 2021, and EQL's ambition is to offer the product in all interesting markets in Europe and elsewhere via out-licensing.

H.A.C. Pharma is one of the most successful pharmaceutical companies in the treatment of ADHD in France with extensive resources in sales and marketing.

In the ADHD patient group insomnia is very common, often exacerbated by treatment with central stimulants such as methylphenidate or dexamphetamine. In Sweden, melatonin treatment for children with ADHD and sleep disorders has reached a total treatment volume of well over 60 million tablets per year, distributed among several products, including Mellozzan. In France melatonin treatment for insomnia has so far not been available to patients with ADHD suffering from insomnia, so Mellozzan will help fill this clear need among both patients and caregivers.

The agreement includes 200,000 EUR in down payment and regulatory milestones and the royalty on sales is well into the double-digit domain. The launch of Mellozzan in France will take place as soon as possible, mainly governed by processing times at French authorities for registration and reimbursement.

EQL Pharma has advanced negotiations regarding Mellozzan with several other companies for additional countries in and outside of Europe.

This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-05-2022 11:47 CET.

For further information, please contact:

Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

Författare Cision